ArticleEuropean journal of nuclear medicine and molecular imaging2025
PSMA PET/CT in biochemical recurrence of prostate cancer with PSA levels ≤ 0.2 ng/mL: a German multicenter analysis of conventional PSMA tracers, including [
Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Bridging the PSMA PET/CT access gap in prostate cancer: evidence, barriers, and priorities for implementation.World journal of urology · 2026Review
- Diagnostic Value of Routine Delayed Pelvic Imaging for Patients with Biochemical Recurrence of Prostate Cancer UndergoingJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Review
- Early detection and localization of recurrent prostate cancer using [Formula: see text]F-DCFPyL PET/CT in patients with low and ultra-low PSA levels.EJNMMI research · 2026Article
- Zirconium-89-based PSMA PET/CT with delayed imaging for early detection of biochemical recurrence in prostate cancer patients with PSA ≤ 0.2 ng/mL: A feasibility study.European journal of nuclear medicine and molecular imaging · 2026Article
- Bimodal PET/CT and PET/MRI imaging in multiple myeloma/prostate cancer restaging and response to BCMA-targeted CAR T-therapy assessment.European journal of nuclear medicine and molecular imaging · 2026Article
- Impact of PSMA-Based Radiopharmaceuticals on the Clinical Management of Prostate Cancer.Cancers · 2026Article
- [European journal of nuclear medicine and molecular imaging · 2026Article
- PSMA PET/CT improves precision diagnosis, treatment, and clinical decision-making in prostate cancer.American journal of translational research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate-specific membrane antigen (PSMA)-directed positron emission tomography/computed tomography (PET/CT) has emerged as a highly accurate imaging modality for detecting tumor lesions in patients with biochemical recurrence (BCR) of prostate cancer (PC). While detection rates of lesions suspicious for PC relapse are known to increase with rising prostate-specific antigen (PSA) levels, data on the efficacy of PSMA PET/CT at very low PSA values (≤ 0.2 ng/mL) remain limited.
methodsIn this multicenter study, we analyzed 321 patients with BCR and a PSA value ≤ 0.2 ng/mL across five German academic centers, using three different PSMA-targeted radiotracers: [
resultsThe overall pooled detection rate was 29.6%. No statistically significant differences in detection rates were observed between the three radiotracers ([
conclusionAll three radiotracers demonstrated comparable diagnostic performance, with no significant superiority observed between the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.